Novartis Ag (NVS)

Trade NVS now with
12/13/2022 10:05:21 AM Novartis Presents Phase III Data Demonstrating Oral Monotherapy Iptacopan Superiority Over Anti-C5
12/8/2022 1:29:58 AM Novartis Says Phase III APPOINT-PNH Study Of Oral Monotherapy Iptacopan Meets Primary Endpoint
12/5/2022 1:36:11 AM Novartis Says Phase III PSMAfore Study With PluvictoTM Meets Primary Endpoint
11/30/2022 10:14:03 AM Novartis Says On Track To Achieve 2025 Targets
10/25/2022 1:03:55 AM Novartis Q3 EPS $0.73; Core EPS $1.58
10/24/2022 1:40:23 AM Novartis Says Phase III APPLY-PNH Trial Meets Two Primary Endpoints For Superiority Over Anti-C5 Treatment
10/14/2022 7:14:59 AM Novartis Gets Positive CHMP Opinion For Pluvicto For Progressive, PSMA-positive Metastatic Castration-resistant Prostate Cancer
9/21/2022 1:12:38 AM Novartis Plans To Petition U.S. Supreme Court To Uphold Validity Of Gilenya Dosing Regimen Patent
9/19/2022 1:45:37 AM Novartis Says ROSALIA Phase I/III Clinical Trial Study Meets Primary Endpoints
9/15/2022 1:51:22 AM Novartis: COMCO Investigating A Patent Assertion In The Field Of Dermatology Treatments